THE POWER OFx RARE DISEASE IN CNS AND NEUROMUSCULAR CONDITIONS. Experts. Experience. Execution. OUR INTEGRATED APPROACH
|
|
- Beryl Rice
- 5 years ago
- Views:
Transcription
1 THE POWER OFx RARE DISEASE IN CNS AND NEUROMUSCULAR CONDITIONS Experts. Experience. Execution. Deep Dive: Rare Disease in CNS and Neuromuscular Conditions Accelerate your next study with Medpace s noted medical and regulatory experts, highly experienced clinical trial management teams, central labs, and core imaging labs. As a therapeutically-focused CRO, Medpace specializes in the design and conduct of global trials in neurology and psychiatry, including rare neurological disorders. We bring a global footprint, strategic medical, regulatory and operational leadership as well as fully integrated Central Labs and Core Imaging Services to enhance and expedite development. Highly relevant operational know-how and subject matter expertise in managing and executing rare disease studies OUR INTEGRATED APPROACH End-to-end suite of global imaging services seamlessly integrated into the overall structure of the trial Experience Core Imaging A well-profiled network of sites and access to patient advocacy groups, KOL relationships and timely enrollment and high-quality conduct of trials. Recruitment & Site Relationships Global Labs A wide range of relevant biomarker assays through our wholly-owned central & bioanalytical lab network
2 Page 2 of 6 CNS Rare Disease Experience Medpace combines its team of neurologists with their cross-functional team of rare disease experts to support Sponsors developing therapies for rare neurological disorders. Medpace has conducted more than 80 global rare disease trials covering Phase I-IV, involving 1,702 sites and 5,768 patients. We have amassed experience in various rare neuromuscular indications such as: Facioscapulohumeral Muscular Dystrophy (FSHD) Pompe Disease Duchenne Muscular Dystrophy Mucopolysaccharidosis Sleep Wake Disorder Huntington s Disease Multiple System Atrophy Friedreich s Ataxia Charcot-Marie-Tooth Disease (CMT) Smith-Magenis Syndrome Medpace also has the expertise and processes in place to conduct trials in disorders that have similar endpoints including all types of muscular dystrophy, spinal muscular atrophy, myasthenia gravis, Fabry, ALS, etc. Recruitment and Global Site Relationships Due to the unique challenges associated with rare disease studies, partnering with a CRO with expertise in enrolling rare disease patients and maximizing site selection to create realistic study feasibility is crucial. Medpace understands this challenge. Our multi-dimensional recruitment model enables us to implement innovative, comprehensive, and customized recruitment and retention strategies that identify, recruit, and retain members of specific patient populations. Medpace has also established a productive network of key clinical sites and large academic institutions who specialize in CNS rare disease disorders ensuring study timelines and key milestones are achieved. Our physicians and professional staff have in-depth knowledge of screening tools and rater scales and will provide oversight for rater services including subjective assessments, inter-rater reliability, and scale validation. Scientifically-Driven Clinical Research Medpace is unique in its scientifically-driven approach to clinical research. The Medpace model gives you the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Our highly experienced medical doctors provide strategic direction for study design and planning, train operational staff, work with Investigators, provide medical monitoring, and meet with regulatory agencies. In addition, our medical monitors work collaboratively with our global regulatory affairs experts to provide strategic guidance into the best pathways to accelerate approval. Relationships with Patient Advocacy Groups Medpace recognizes the importance of collaborating with advocacy groups. Although advocacy groups vary greatly in size, scope, and purpose, they regularly offer insight into who is treating patients, what is important to patients, and lessons learned from past clinical trials. Advocacy group collaboration raises awareness for your clinical trial and can be an invaluable partnership for the life of your drug. Medpace is well versed in working with sponsors and advocacy groups of all different sizes globally in order to ensure clinical trials are designed and operated with the patients in mind. Medpace can help sponsors forge new relationships with advocacy groups or support existing relationships seemlessly.
3 Page 3 of 6 Meet our Medical Experts Terence Eagleton, MBBS, BSc Senior Medical Director, Rare Diseases Sarah DeRossett, MD, PhD Senior Medical Director, Neurology Richard Scheyer, MD Vice President, Medical Affairs, Neurology, Pharmacology James Vornov, MD, PhD Vice President, Medical Affairs, Neurology, Analgesia, Psychiatry Thomas Thompson, MD Vice President, Medical Affairs, Psychiatry, Neurology Rare Disease Terence Eagleton, MBBS, BSc Senior Medical Director, Rare Diseases Dr. Terence Eagleton is an accomplished pharmaceutical physician who has worked in the biopharma industry for over 17 years. He has worked in all phases of international clinical research and global medical affairs in a wide variety of therapeutic areas but with a particular focus on rare metabolic and endocrine disorders. During his career, he has contributed significantly to the clinical development and commercialization of numerous innovative therapies for rare and ultra-rare indications that include, but are not limited to, Morquio Syndrome Type A, Hunter Syndrome, Hurler Syndrome, Gaucher Disease, Anderson-Fabry Disease, Lysosomal Acid Lipase Deficiency, Pompe Disease, Hereditary Angioedema, and X-linked Hypophosphatemia. Dr. Eagleton received his Bachelor of Science Degree (Honours) in Physiology and Medical Degree at University College London and following qualification, trained as a surgeon with a particular interest in Trauma Management and Patient Critical Care. Neurology Sarah DeRossett, MD, PhD Senior Medical Director, Neurology Dr. DeRossett is a board certified neurologist with more than 25 years of academic, clinical, and pharmaceutical research experience. Prior to joining Medpace, she served as VP of Clinical Research and Medical Affairs at a small, specialty pharmaceutical company and was a Senior Medical Director and Project Physician Leader at a large, global pharmaceutical company, where she served as the single point of accountability for the global clinical development of new medicines across a variety of neuroscience therapy areas. Her drug development experience spans Phases I-IV and includes neurodegenerative and rare diseases. She has led or directly supported drug development programs resulting in two European Medicines Agency and four FDA approvals. Dr. DeRossett earned her medical degree from the Emory University School of Medicine and completed her Neurology training at Johns Hopkins. She also holds a PhD in Neural and Behavioral Studies and was formerly on the faculty at Emory. Richard Scheyer, MD Vice President, Medical Affairs, Neurology, Pharmacology Dr. Richard Scheyer is a board certified neurologist with over 30 years of professional medical experience which includes 20 years dedicated to clinical drug development. He is a pioneer in translational medicine and Phase I/II drug development, with special interest in early demonstration of clinical efficacy. Dr. Scheyer received his B.S. in Physics from Stanford University, his M.D. from The State University of New York, Upstate Medical University, and completed residency training in Neurology and fellowship training in Epilepsy and Clinical Pharmacology at Yale University before joining the Yale faculty, serving as Associate Professor of Neurology. Prior to joining Medpace, Dr. Scheyer held a number of leadership roles at biopharmaceutical firms where he was responsible for clinical, biomarker, and pharmacogenomic strategy and execution for more than 70 development candidates across therapeutic areas. Experience includes small molecule, macromolecular, and genetic therapies for common and rare neurologic disease.
4 Page 4 of 6 James Vornov, MD, PhD Vice President, Medical Affairs, Neurology, Analgesia, Psychiatry Dr. Vornov is an internationally known clinician-scientist with broad experience in both neuroscience and CNS drug development. He has worked in multiple CNS therapeutic areas having directed programs in depression, suicidal ideation, Parkinson s disease, stroke, neuropathic pain, diabetic and chemotherapy-induced peripheral neuropathy, anesthesia and brain tumors. He has particular expertise in the rapid transition of compounds from the laboratory to clinical proof of concept through the use of technologies such as biomarkers, PK/PD modeling, adaptive design and clinical trial simulation. Dr. Vornov received his B.A. in Biology from Columbia University and his M.D. and Ph.D. from Emory University School of Medicine. He trained in Neurology at the Johns Hopkins Medical School where he served on the faculty for 10 years prior to transitioning to industry. Psychiatry Thomas Thompson, MD Vice President, Medical Affairs, Psychiatry, Neurology Dr. Thompson is Board Certified in Psychiatry and Geriatric Psychiatry with clinical development experience in numerous indications including Parkinson s disease, bipolar disorder, stroke, epilepsy, depression, schizophrenia, anxiety disorders, and pain. He has co-authored a book chapter on the genetics of bipolar disorder and has been published in numerous peer reviewed journals. Dr. Thompson has held leadership roles in the pharmaceutical industry and has a depth and breadth of experiences including medical affairs, global clinical development, regulatory submissions, medical governance, and medical monitoring. He received his B.S. in biology from the University of Central Florida, his M.D from Temple University School of Medicine, and his Psychiatry and Geriatric Psychiatry certificate from Emory University School of Medicine.
5 Page 5 of 6 Medpace Global Labs Provide Safety and Biomarker Analysis Medpace s central laboratory has supported over 45 studies from Phase I through Phase IV in the following CNS indications: CNS and Neuromuscular Diseases Acute Ischemic Stroke Alzheimer s Charcot-Marie-Tooth Disease Duchenne Muscular Dystrophy Epilepsy Familial Amyloid Neuropathy Familial Amyloid Polyneuropathy Huntington s Disease Jet Lag Lennox-Gastaut Syndrome Major Depressive Disorder Migraine Multiple Sclerosis Mytonic Dystrophy Neurological Disorders Non-24 Hour Sleep-wake Disorder Opioid Dependence Pain Postpartum Depression Sleep Disorders Stroke Medpace Labs provide consistency in methods and instrumentation across wholly-owned and purpose-built laboratories located in the US, Europe, China and Singapore. We offer a wide range of relevant safety and biomarker assays and have the ability to rapidly establish and validate novel assays as needed. Laboratory Testing Safety Testing Chemistry Serology Hematology Urinalysis Drugs of Abuse Screening Thyroid Testing Coagulation Cystatin C (Serum) IL-6 (Serum) {NSE) Neuron-specific enolase (Serum) S100 (Serum) Inflammatory Biomarkers (Serum) Genotyping Cerebral Spinal Fluid Testing (CSF) Total Tau (CSF) Neurofilament Light Chain (CSF) Neurogranin (CSF) YKL-40 (CSF) Validated Medpace Lab Partner Network *There may be some tests / biomarkers requested that are not on the central lab test menu. Although those biomarkers may not currently be on Medpace s validated menu, they are available via Medpace s laboratory partners. These assays may be candidates as new validations to the Medpace in house test menu. Each year Medpace validates over 70 new assays based on guidelines from the Clinical and Laboratory Standards Institute (CLSI) and in accordance with CAP and CLIA regulations.
6 Page 6 of 6 Core Imaging Expertise for Neuromuscular Studies High-quality image acquisition and interpretation is crucial for the success of trials relying on neuroimaging for patient selection or as a primary endpoint. Medpace provides centralized neuroimaging expertise, led by radiologists and neurologists with decades of clinical and trial experience. Medpace Imaging Core Lab provides an end-to-end suite of imaging services to enhance and expedite biopharmaceutical and imaging contrast agent development, including a broad spectrum of imaging biomarkers for DMD trials. Capabilities include: MR Spectroscopy T2 Mapping Muscle Fat Fraction PDFF Complex MR Elastography ClinTrak EDC epro/ediary ClinTrak EDC, Medpace s proprietary clinical trial management system, has an epro/ediary component that allows for the safe and secure collection of PRO data directly from patients through multiple platforms. This component not only offers a flexible, highly customized patient interface but the patient-entered data is immediately integrated in the ClinTrak EDC database allowing Sponsors, research sites, Medpace teams and other permitted users web-based access to study data at all times. A Full-Service Approach to Clinical Research Driven by a full-service CRO model that coordinates and integrates all services for our clients, Medpace provides an accountable, seamless, integrated and efficient platform for executing clinical research increasing quality and speed while significantly reducing the need for duplicate management oversight. Our disciplined processes, site relationships, and technologies enable us to execute even the most complex global studies, from first-in-human through post-approval. Medical Affairs Regulatory Affairs and Medical Writing Clinical Monitoring Clinical Trial Management Biometrics and Data Sciences Safety and Pharmacovigilance Quality Assurance Global Labs, Imaging & Cardiovascular Core Labs medpace.com info@medpace.com North America Latin America Europe Asia Pacific Middle East Africa
PSYCHIATRY. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Psychiatry. Scientifically-Driven Clinical Development
THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Psychiatry Incidences of mental disorders such as depression, bipolar, anxiety disorders, and schizophrenia continue to grow around the
More informationNEUROSCIENCE. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Neurology. Scientifically-Driven Clinical Development
THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Neurology Medpace supports our sponsors who are advancing new neurological products by providing specialized expertise in the design and
More informationSUBSTANCE USE DISORDERS
THE POWER OFx SUBSTANCE USE DISORDERS Experts. Experience. Execution. Deep Dive: Substance Use Disorder Clinical Research Accelerate your next substance use disorder study with Medpace s noted medical
More informationSTROKE CLINICAL RESEARCH
THE POWER OFx STROKE CLINICAL RESEARCH Experts. Experience. Execution. Deep Dive: Stroke Clinical Research Accelerate your next stroke study with Medpace s noted medical and regulatory experts, highly
More informationRARE DISEASE. THE POWER OFx. Experts. Experienc e. Execution. Challenges Conducting Rare Disease Studies. Experts: Experience: Execution:
THE POWER OFx TM Experts. Experienc e. Execution. The Power of X in Rare Disease Experts: Committed cross-functional team of Rare Disease experts comprised of doctors, project managers, regulatory consultants,
More informationMedpace, a pioneer in the development of therapeutics to treat metabolic disorders, is your first stop for compound development in lipid studies.
THE POWER OFx MEDPACE ADVANTAGE FOR LIPID STUDIES Experts. Experience. Execution. Medpace, a pioneer in the development of therapeutics to treat metabolic disorders, is your first stop for compound development
More informationHEMATOLOGY AND ONCOLOGY
x THE POWER OF HEMATOLOGY AND ONCOLOGY Experts. Experience. Execution. A Deeper Dive into Hematology and Oncology Medpace supports our sponsors who are advancing new anti-cancer therapies by providing
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationCognitive Research Corporation
Cognitive Research Corporation Contract Research Organization offering specialized expertise to fit the unique needs of each client Bobbie Theodore clinicaltrials@alliancesites.com An Alliance of Quality
More informationPEDIATRICS. THE POWER OFx. Experts. Experienc e. Execution. Conducting Pediatric Studies Presents Great Challenges. Experts: Experience: Execution:
THE POWER OFx Experts. Experienc e. Execution. Medpace combines expertise, experience and execution for a winning combination in pediatric studies Experts: Key pediatricians on staff who are trained in
More informationCARDIOVASCULAR. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Cardiovascular Clinical Development
THE POWER OFx A Deeper Dive into Cardiovascular Clinical Development As a therapeutically-focused CRO with a long history in supporting drugs, biologics, and medical devices for cardiovascular disease,
More informationIsrael Makov President and Chief Executive Officer Teva
Israel Makov President and Chief Executive Officer Israel Makov has been the President and Chief Executive Officer of since April 2002. Previously he served as 's Chief Operating Officer from January 1,
More informationPEDIATRICS. THE POWER OFx. Experts. Experienc e. Execution. Conducting Pediatric Studies Presents Great Challenges. Experts: Experience: Execution:
THE POWER OFx Experts. Experienc e. Execution. Medpace combines expertise, experience and execution for a winning combination in pediatric studies Experts: Five key pediatricians on staff who are trained
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationParkinson s Institute and Clinical Center Appoints Anthony Santiago, M.D., Neurologist and Movement Disorders Specialist as Chief Medical Officer
Press Release For Immediate Release October 30, 2017 Contact: Chris Di Salvo Mobile: (408) 506-0455 E-mail: profeff@aol.com Parkinson s Institute and Clinical Center Appoints Anthony Santiago, M.D., Neurologist
More informationStrategic Plan Executive Summary Society for Research on Nicotine and Tobacco
Strategic Plan 2013 2017 Executive Summary Society for Research on Nicotine and Tobacco Prepared By: Corona Insights Corona Insights, 2012 CoronaInsights.com CONTENTS Introduction... 1 Background... 1
More informationBoehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider
Boehringer Ingelheim Biopharmaceuticals in China Your Reliable Contract Manufacturing Solution Provider Dr. Bin Wang, Dr. Axel Schleyer Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. Contact:
More informationAUSTRALIA'S ONLY DEDICATED ACADEMIC DEPARTMENT OF NEUROSCIENCE.
AUSTRALIA'S ONLY DEDICATED ACADEMIC DEPARTMENT OF NEUROSCIENCE www.monash.edu/medicine/ccs/neuroscience Ocular motor testing is important as an overall measure of brain function 2 MONASH UNIVERSITY DEPARTMENT
More informationRobin Feldman, MBA & Joy Esterlitz, MS NINDS CDE Team The Emmes Corporation Rockville, MD USA. Thursday, September 14, 2017
The National Institute of Neurological Disorders and Stroke (NINDS) and American Academy of Cerebral Palsy and Developmental Medicine (AACPDM) Cerebral Palsy Common Data Elements (CDE) Recommendations
More informationHOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK
HOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of
More informationPartnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC
Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC The patients are waiting. Dr. Paul Janssen To Our Potential
More informationExcellence in Trial Management
Excellence in Trial Management COMPANY OVERVIEW Privately held company Founded in 2007 Contract Research Organization HQ in Montréal, Canada Specialized in Clinical Development & Trial Management Client
More informationParkinson s Foundation Nurse Course Faculty
* Planning Committee Parkinson s Foundation Nurse Course Faculty * Julie Carter, RN, MN, ANP Ms. Carter is a nurse practitioner and Professor of Neurology at Oregon Health and Science University. She received
More informationA Deeper Dive into Hematology and Oncology
DEEP DIVE A Deeper Dive into Hematology and Oncology Medpace supports our sponsors who are advancing new anti-cancer therapies by providing specialized expertise in the design and management of your programs.
More informationAchieving Operational Excellence in Prospective Observational Research
Achieving Operational Excellence in Prospective Observational Research Louise Parmenter PhD, MSc VP, Global Head of Operations, Epidemiology & Outcomes Research Ombretta Palucci Senior Director, EMEA RWLP
More informationHEALTHSTREAM LIVING LABS IN ACTION
HEALTHSTREAM LIVING LABS IN ACTION A CONVERSATION WITH: Mitchel T. Heflin MD, MHS Associate Professor of Medicine, Duke University School of Medicine Eleanor McConnell PhD, RN, GCNS-BC Associate Professor,
More informationInternational Neurology Conference
International Neurology Conference December 3-5, 2018 Valencia, Spain Media Partners and Collaborations Conference Invitation Madridge Conferences is pleased to welcome you to the International Neurology
More informationHow Medpace Addresses the Unique Challenges in Rare Disease Clinical Research
THE POWER OFx Experts. Experience. Execution. How Medpace Addresses the Unique Challenges in Rare Disease Clinical Research Applying lessons learned, innovative thinking, and creative problem solving By
More informationDIFFERENTIATING CRO-SPONSOR PARTNERSHIPS THE WORLDWIDE WAY
DIFFERENTIATING CRO-SPONSOR PARTNERSHIPS THE WORLDWIDE WAY FROM TRANSACTIONAL TO TRANSLATIONAL Outsourcing in Clinical Trials Israel Angelico Carta, MD 20 March 2018 EXPERIENCED MANAGEMENT Neal R. Cutler,
More informationSTRATEGIC PLAN
STRATEGIC PLAN 2016 2020 Promoting and supporting excellence in research www.immunology.org BSI STRATEGY 2016 2020 EXECUTIVE SUMMARY OUR MISSION Our mission is to promote excellence in immunological research,
More informationAddressing Gaps in MS Care. November 6, :00 AM - Noon
Addressing Gaps in MS Care November 6, 2015 11:00 AM - Noon Learning Objectives Understand and confidently communicate the barriers to MS care caused by the shortage of healthcare providers with MS experience,
More informationReady for a CRO That Values Performance Over Promises? CHALLENGE. At Clinipace, it s personal.
Ready for a CRO That Values Performance Over Promises? CHALLENGE At Clinipace, it s personal. Who We Are At Clinipace, It s Personal. We Will PROVE IT. With us, you get the A team. We deliver a level of
More informationTime Topic / Activity Presenter(s)
Social Innovation Fund Pre-Launch Training Agenda September 14, 2013 Time Topic / Activity Presenter(s) 8:00 REGISTRATION 8:30 Welcome - JAHF and AIMS Center Introductions 8:50 Agenda & Materials Review
More informationQiG INS Conference May 22, 2011
Strategy & Vision Growth Electrochem Medical Device Evolution QiG Cardio vascular QiG INS Conference May 22, 2011 Greatbatch Medical Neuro modulation 1 GREATBATCH TODAY 2010 Revenue by Product Line NYSE:
More informationTREATING NEUROINFLAMMATION, TREATING DISEASE
TREATING NEUROINFLAMMATION, TREATING DISEASE NeuroTherapia Developing novel biopharmaceuticals for the treatment of neuroinflammatory disorders NOVEL STRATEGY FOR REDUCING NEUROINFLAMMATION SIGNIFICANT
More informationABA. The American Board of Anesthesiology. Media Kit
ABA The American Board of Anesthesiology Media Kit ABOUT THE ABA The American Board of Anesthesiology (ABA) is a nonprofit organization whose mission is to advance the highest standards of the practice
More informationALS ACT (Accelerated Therapeutics)
ALS ACT (Accelerated Therapeutics) Request for Proposals: Phase II Clinical development of novel, high-potential treatments for people with ALS Release Date 23 October 2015 Letter of intent due: November
More informationannual report
2010-11 annual report A year in motion Annual Report From the director The past year has been one of substantial achievement for the Virginia Commonwealth University Parkinson s Disease Center. As a result
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More informationTranslational Cardiac Stem Cell Program ( TCSCP )
Translational Cardiac Stem Cell Program ( TCSCP ) 2017 Developing Revolutionary Treatments for Multiple Diseases Dr. Yerem founded the TCSCP in 2003 to develop revolutionary treatments for life threatening
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More information20% A Holistic Approach Built on Evidence OF U.S. ADULTS EXPERIENCE MENTAL ILLNESS EACH YEAR
BEHAVIORAL HEALTH NEARLY 20% OF U.S. ADULTS EXPERIENCE MENTAL ILLNESS EACH YEAR Source: SAMHSA, 2018. Key substance use and mental health indicators in the United States: Results from the 2017 National
More informationTHE BRITISH COLUMBIA NEUROPSYCHIATRY PROGRAM
THE BRITISH COLUMBIA NEUROPSYCHIATRY PROGRAM THE PROVINCIAL CLINICAL-ACADEMIC NEUROPSYCHIATRY PROGRAM BASED IN VANCOUVER, CANADA SEPTEMBER 16, 2016 Dr. Islam Hassan, MBChB, MMedSc, MRCP(UK), MRCPsych,
More informationParkinson s Research and the New Centre for Brain Health at UBC. Case for Support The University of British Columbia Faculty of Medicine
Parkinson s Research and the New Centre for Brain Health at UBC Case for Support The University of British Columbia Faculty of Medicine THE VALUE OF A HEALTHY BRAIN By 2020, brain disease will overtake
More informationTREAT-NMD Conference 2013
TREAT-NMD Conference 2013 Utility of patient registries for clinical care and post-marketing surveillance Jan Verschuuren Leiden University Medical Centre Newcastle 30 October 1 November 2013 2 Improving
More informationThe Journey towards Total Wellbeing A Health System s Innovative Approach
The Journey towards Total Wellbeing A Health System s Innovative Approach Company Profile Wellness A state of complete physical, mental and social wellbeing and not merely the absence of disease or infirmity
More informationEPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets
EPIDEMIOLOGY Accurate, in-depth information for understanding and assessing targeted markets WHY ACCURATE MARKET FORECASTS Start with accurate understanding Epidemiology is the study of disease patterns
More informationThe UW Medicine Neurosciences Institute
The UW Medicine Neurosciences Institute is a multi-disciplinary team that diagnoses and treats disorders of the nervous system. Our physicians conduct world class research, and combine the latest technology
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationREPORT TO CONGRESS Multi-Disciplinary Brain Research and Data Sharing Efforts September 2013 The estimated cost of report or study for the Department of Defense is approximately $2,540 for the 2013 Fiscal
More informationJoint Programming Initiative on Neurodegenerative Diseases. Prof. Philippe Amouyel Chair, JPND Management Board
Joint Programming Initiative on Neurodegenerative Diseases Prof. Philippe Amouyel Chair, JPND Management Board Cases / 100 Alzheimer s disease in Europe 40 Number of cases Societal costs ( ) 2010 6,000,000
More informationFELLOWSHIP OPPORTUNITIES ADVANCE UNDERSTANDING OF AUTISM SPECTRUM DISORDER (ASD)
OPPORTUNITIES ADVANCE UNDERSTANDING OF AUTISM SPECTRUM DISORDER (ASD) PREDOCTORAL OPPORTUNITIES Marcus Autism Center, in conjunction with Children s Healthcare of Atlanta and Emory University School of
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationAnnual General Meeting 25 October Cogstate Ltd. All rights reserved.
Annual General Meeting 25 October 2017 2017 Cogstate Ltd. All rights reserved. Board of Directors Audit, Risk & Compliance Committee Remuneration & Nomination Committee Martyn Myer Non-Exec Chairman Yes
More informationCELEBRATING 169 YEARS OF TRADITION AND TRANSFORMATION IN HEALTHCARE RESEARCH
CELEBRATING 169 YEARS OF TRADITION AND TRANSFORMATION IN HEALTHCARE RESEARCH Our MISSION Building on our tradition Reaching out to the community Doing our best to serve, care and heal Together, we aim
More informationMind the Moment Instructors
Mind the Moment Instructors Tara Healey Tara is the director of Harvard Pilgrim Health Care s Mind the Moment mindfulness program. Since 2006, Tara has been developing mindfulness workshops and courses
More informationWITH ADDICTION EX P ERTS. addiction-certificate.psychiatry.ufl.edu
TR A I N WITH ADDICTION EX P ERTS addiction-certificate.psychiatry.ufl.edu Position yourself for success with specialized training in addiction evaluation, counseling and treatment from a top addiction
More informationSciVal Research Intelligence Tool
0 SciVal Research Intelligence Tool Alexander van Servellen Consultant, Elsevier Research Intelligence a.vanservellen@elsevier.com Mahidol University, May 21st 2015 1 Context Mahidol University subscribes
More informationAPTA EDUCATION STRATEGIC PLAN ( ) BOD Preamble
APTA EDUCATION STRATEGIC PLAN (2006-2020) BOD 03-06-26-67 Preamble The content of the Education Strategic Plan represents the specific initiatives the American Physical Therapy Association (Association)
More informationNAVIFY Tumor Board NAVIFY
NAVIFY Tumor Board Make the most informed personalized treatment decisions possible by leveraging innovative technologies and the latest scientific and clinical data WHAT S INSIDE Key Takeaways NAVIFY
More informationEASTERSEALS MIDWEST AUTISM CONFERENCE SERIES
EASTERSEALS MIDWEST AUTISM CONFERENCE SERIES SPONSORED BY KANSAS CITY CAPE GIRARDEAU SPRINGFIELD COLUMBIA ST. LOUIS KANSAS CITY NOVEMBER 14 8:30 am 4:30 pm JOIN US. eastersealsautismseries.com Kauffman
More informationFELLOWSHIP OPPORTUNITIES ADVANCE THE UNDERSTANDING OF AUTISM SPECTRUM DISORDER (ASD)
OPPORTUNITIES ADVANCE THE UNDERSTANDING OF AUTISM SPECTRUM DISORDER (ASD) PREDOCTORAL OPPORTUNITIES Marcus Autism Center, in conjunction with Children s Healthcare of Atlanta and Emory University School
More informationRe: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities
Public Policy Division 202.393.7737 p 1212 New York Ave NW 866.865.0270 f Suite 800 www.alz.org Washington, DC 20005 Roderick Corriveau, Ph.D. Program Director National Institute of Neurological Disorders
More informationPosition Specification
Position Specification Empirical Spine, Inc. Title: Vice President, Clinical & Regulatory Affairs Opportunity: The Vice President, Clinical & Regulatory Affairs will play a key role in the success of this
More information2016 ADHD Conference Speaker Biographies
2016 ADHD Conference Speaker Biographies Dr. Rosemary Tannock, PhD Rosemary Tannock is now Professor Emerita at the University of Toronto and continues as a Senior Scientist at the Hospital for Sick Children
More informationContinuing Medical Education the Joslin Way:
Continuing Medical Education the Joslin Way: Superior content Content produced by the most respected experts in diabetes and its related conditions, ensuring that each academic program is timely, accurate,
More informationDigestive & Metabolic Diseases
4 th World Congress on Digestive & Metabolic Diseases October 29-30, 2018 San Francisco, California, USA Invitation Dear Attendees, We are glad to announce the 4 th World Congress on Digestive & Metabolic
More informationBritish Association of Stroke Physicians Strategy 2017 to 2020
British Association of Stroke Physicians Strategy 2017 to 2020 1 P age Contents Introduction 3 1. Developing and influencing local and national policy for stroke 5 2. Providing expert advice on all aspects
More informationAnti-Infective Clinical Trials
Anti-Infective Clinical Trials The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting
More informationMSc In Translational Neuroscience.
Faculty Of Medicine Dentistry & Health. Faculty Of Science. MSc In Translational Neuroscience. www.sheffield.ac.uk/transneuro MSc in Translational Neuroscience. Why translational neuroscience? Translational
More informationConnecting the Dots: Alzheimer s PCPRN and the Learning Health System
Connecting the Dots: Alzheimer s PCPRN and the Learning Health System MaryAnne Sterling Healthcare Activist Family Caregiver @SterlingHIT December 9, 2016 2 3 Thumbnail Sketch 20+ years as caregiver, healthcare
More informationAccelerating Translation at Dana-Farber Cancer Institute*
Accelerating Translation at Dana-Farber Cancer Institute* *and our partner institutions February 12, 2013 Edward J Benz JR, MD Dana Farber Cancer Institute 1 2 Academic Structure All Dana-Farber faculty
More informationigh-sensitivity Cardiac Troponin - A Canadian Viewpoint from CIHR funded studies Friday May 30, 2014
8:50-9:00 Welcome and Introduction Juravinski Cancer Center Lecture Theatre (4 th floor) 699 Concession St. Hamilton, ON L8V 5C2 Introduction to High-Sensitivity Cardiac Troponin Current State 9:00-9:45
More informationSaint Mary s College High Potential Program Peer Mentor (FWS Position)
1 Saint Mary s College High Potential Program 2013-2014 Peer Mentor (FWS Position) THE HIGH POTENTIAL PROGRAM: The High Potential (HP) Program includes a Summer Bridge Program that provides access, admission
More informationTAKEDA NEUROSCIENCE BRINGING INNOVATIVE MEDICINES TO PATIENTS FOR WHOM THERE ARE NO TREATMENTS AVAILABLE
TAKEDA NEUROSCIENCE BRINGING INNOVATIVE MEDICINES TO PATIENTS FOR WHOM THERE ARE NO TREATMENTS AVAILABLE EMILIANGELO RATTI, PHD Head, Neuroscience Therapeutic Area WE HAVE TAKEN ON THE CHALLENGE TO ALLEVIATE
More informationPOLICY FRAMEWORK FOR DENTAL HYGIENE EDUCATION IN CANADA The Canadian Dental Hygienists Association
POLICY FRAMEWORK FOR DENTAL HYGIENE EDUCATION IN CANADA 2005 The Canadian Dental Hygienists Association October, 2000 Replaces January, 1998 POLICY FRAMEWORK FOR DENTAL HYGIENE EDUCATION IN CANADA, 2005
More informationInvestor Presentation September Cogstate Ltd. All rights reserved.
Investor Presentation September 2017 2017 Cogstate Ltd. All rights reserved. We believe that brain health is profoundly important to quality of life and should be easier to measure. That s why we so passionately
More informationCleveland Clinic Laboratories Hematology Diagnostic Services. Trust in us for everything you need in a reference lab.
Cleveland Clinic Laboratories Hematology Diagnostic Services Trust in us for everything you need in a reference lab. Our Mission The Pathology and Laboratory Medicine Institute contributes to excellent
More informationAlzheimer Europe Conference Berlin, 2-4 October Special Symposium 4 October, , Room II. Eli Lilly and Company
ENGAGING WITH PATIENT ORGANISATIONS WITHIN IMI CONSORTIA TO INFORM QUALITY, RELEVANCE AND VALUE IN ALZHEIMER S RESEARCH INSIGHTS FROM MOPEAD, EPAD AND ROADMAP Alzheimer Europe Conference Berlin, 2-4 October
More informationSURVEY REPORT CLINICAL TRIALS: PAST, PRESENT AND FUTURE
SURVEY REPORT CLINICAL TRIALS: PAST, PRESENT AND FUTURE + OVERVIEW Clinical trials have changed dramatically in the last 10 years. Sponsors are increasingly pressured to get drugs to market faster and
More informationPersonalized medecine Biomarker
Patient Disease Diagnosis Risk prediction Personalized medecine Biomarker Targeted therapies Diagnostic Theranostic: Efficay Toxicity Treatment 1 THE CASE FOR PERSONALIZED MEDICINE IS COMPELLING.. Toxicity
More informationHELPING DELIVER LIFE-CHANGING THERAPIES VACCINE DEVELOPMENT
HELPING DELIVER LIFE-CHANGING THERAPIES VACCINE DEVELOPMENT PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT With more than 25 years of vaccine development experience for both government and
More informationCountry Participation: An Overview for Interested Investigators
Country Participation: An Overview for Interested Investigators 1 Introduction This document provides an overview of the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). If you have any
More informationWho we are. We envision a world where high quality eye health and vision care is accessible to all people.
Who we are The World Council of Optometry (WCO) is an international optometric association founded in 1927. The WCO represents over 200,000 optometrists in more than 60 countries, through almost 300 Country,
More informationThomas C. Wilmot, Sr. Judy Wilmot Linehan
Thomas C. Wilmot, Sr. Judy Wilmot Linehan The Wilmot Family For more than 35 years, the Wilmot family has been dedicated to supporting cancer research and care for the Rochester community. Their generosity
More informationThe Role of the Medical Director in Long Term Care
The Role of the Medical Director in Long Term Care Robert P. Smith MD, CMD President WAMD 5/24/17 WAMD Topics of the Talk Discuss the role of Medical Director Discuss more specifically the medical director
More informationneuromuscular disease
neuromuscular disease Ysbrand Poortman Founder/ board member VSN, Dutch Association for NeuroMuscular Diseases EAMDA, Eur. Alliance Neuromuscular Disease Associations ENMC, Eur. NeuroMuscular Center for
More informationYour Opportunity Begins Here.
Your Opportunity Begins Here. ASN Scientific Councils and Research Interest Sections Share Your Scientific Expertise with Like Minds Through ASN ASN s Scientific Councils and Research Interest Sections
More informationTAKEDA NEUROSCIENCE BRINGING INNOVATIVE MEDICINES TO PATIENTS FOR WHOM THERE ARE NO TREATMENTS AVAILABLE
TAKEDA NEUROSCIENCE BRINGING INNOVATIVE MEDICINES TO PATIENTS FOR WHOM THERE ARE NO TREATMENTS AVAILABLE EMILIANGELO RATTI, PHD Head, Neuroscience Therapeutic Area WE HAVE TAKEN ON THE CHALLENGE TO ALLEVIATE
More informationGHI Year at a Glance. over 850. Key Issues in International Operations CU International Administration Group September 2013
GHI Year at a Glance 2013 Key Issues in International Operations CU International Administration Group September 2013 Small Scale Interdisciplinary Research Awards October 2013 Global Mental Health co-sponsored
More informationProposal for Review of Wilderness Medicine Fellowships. SAEM Fellowship Review Committee (Current as of May 2018) Introduction:
Proposal for Review of Wilderness Medicine Fellowships SAEM Fellowship Review Committee (Current as of May 2018) Introduction: Wilderness Medicine (WM) is the practice of resource-limited medicine in austere
More informationGeriatric Neurology Program Requirements
Geriatric Neurology Program Requirements Approved November 8, 2013 Page 1 Table of Contents I. Introduction 3 II. Institutional Support 3 A. Sponsoring Institution 3 B. Primary Institution 4 C. Participating
More informationWho we are. We envision a world where high quality eye health and vision care is accessible to all people.
Who we are The World Council of Optometry (WCO) is an international optometric association founded in 1927. The WCO represents over 200,000 optometrists in more than 60 countries, through almost 300 Country,
More informationJames Brown Dr. Vincent Gouttebarge
James Brown obtained a joint PhD from UCT and Vrije University Medical Center (Amsterdam) in April 2015. His PhD evaluated the effectiveness of the BokSmart program in reducing rugby- related injuries
More informationPROOF. Accomplishments
Accomplishments 10 Key Accomplishments for For the University of Miami Department of Neurology, 2016 was a year of major accomplishments that have transformed lives for many of those suffering with Stroke,
More informationCTA Strengths. Organisational Structure Board. CTA Board CEO. Background to Cancer Trials Australia What we do well An increasing struggle Conclusions
Models for Clinical Research: Cancer Trials Australia Professor Mark Rosenthal Chairman; Cancer Trials Australia and Director of Medical Oncology, Royal Melbourne Hospital For discussion: Background to
More informationContemporary Orthopedic Care: The O.R. Through Rehabilitation Thursday, June 19, :00am 4:00pm
Alvin C. Ong, MD Chairman Dr. Alvin Ong is a Joint Replacement Surgeon at the Rothman Institute and also serves as the Director of the Orthopaedic Department at AtlantiCare Regional Medical Center and
More informationQuality Management System Certification. Understanding Quality Management System (QMS) certification
Quality Management System Certification Understanding Quality Management System (QMS) certification The medical device manufacturing sector is one of the most regulated sectors in which significant quality
More informationJulian Young Associate
Julian Young Associate Profile Julian Young joined Fire Inside Leadership as an Associate in June 2015. A Certified Professional Co-Active Coach and Certified Team Performance Coach, artful facilitator,
More information